More recently, targeting CD47 by SIRPα-Fc fusion protein or monoclonal antibody combined with azacitidine showed reliable efficacy and safety in some malignant hematological tumors such as myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia in clinical trials [57–60]. Here, SIRPA is linked to acute myeloid leukemia.